ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 222

Characterization of Unexpected Autoantibody Specificities in American Indian SLE Patients

Joseph M. Kheir1, Tim Gross1, Carla J. Guthridge1, Krista Bean1, Virginia C. Roberts1, Joel M. Guthridge2, M. Sohail Khan3, Fabio Mota4, Michael Peercy5, Bobby Saunkeah6 and Judith A. James7, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Cherokee Nation Health Services, Tahlequah, OK, 4Chickasaw Nation Medical Center, Ada, OK, 5Epidemiology, Chickasaw Nation Department of Health, Ada, OK, 6Chickasaw Nation Department of Health, Ada, OK, 7Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoantibodies and health disparities, Native Americans, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Healthcare Disparities in Rheumatology Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

System Lupus Erythematosus (SLE) is an autoimmune disease that is over-represented in the American Indian (AI) population and often manifests as a more severe disease. Although the clinical manifestations can be diverse, nearly all patients share the presence of autoantibodies, including anti-dsDNA and anti-Sm which have high specificity for the disease. American Indian SLE patients often lack reactivity to autoantigens commonly found in SLE patients of other ethnicities. We have observed that sera from 41% of AI SLE patients contain unidentified autoantigenic reactivity by precipitin testing compared to 24% for AA, 17% for EA, and 23% for HA. Therefore the goal of this study is to identify non-traditional autoantibody specificities associated with disease in AI SLE patients.

Methods:

The sera from 100 AI SLE patients, 37 AI unaffected controls, 16 AI unaffected family members, and 17 AI patients with other systemic autoimmune diseases were screened using a 128 autoantigen protein array. Antigen reactivity based on a mean fluorescence intensity three standard deviations above the average of the unaffected negative controls for that antigen were considered positive. Hierarchical clustering of these data was used to identify shared autoantibody reactivities.

Results:

Twenty-two percent (n=22) of all of the positive SLE patients, 19% (n=3) of all positive unaffected family members, and 24% (n=4) of all positive other autoimmune disease samples had reactivity to the M2 mitochondrial antigen typically associated with primary biliary cirrhosis (PBC), an autoimmune liver disease. Furthermore, 91% (n=20) of the M2 positive SLE samples also contained 1 or more autoantibodies specific for or associated with myositis, whereas only 33% (n=1) of M2 positive unaffected family member samples, and 50% (n=2) of the M2 positive samples from individuals with other autoimmune disease contained myositis specific or associated autoantibodies.

Conclusion:

This study suggests that M2 and myositis autoantibodies are associated with disease in American Indian SLE patients. Although SLE patients are often diagnosed with more than one autoimmune disease, the coexistence of SLE and PBC or myositis is rare. The study was funded in part by Native American Research Centers for Health.


Disclosure: J. M. Kheir, None; T. Gross, None; C. J. Guthridge, None; K. Bean, None; V. C. Roberts, None; J. M. Guthridge, None; M. S. Khan, None; F. Mota, None; M. Peercy, None; B. Saunkeah, None; J. A. James, None.

To cite this abstract in AMA style:

Kheir JM, Gross T, Guthridge CJ, Bean K, Roberts VC, Guthridge JM, Khan MS, Mota F, Peercy M, Saunkeah B, James JA. Characterization of Unexpected Autoantibody Specificities in American Indian SLE Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/characterization-of-unexpected-autoantibody-specificities-in-american-indian-sle-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-unexpected-autoantibody-specificities-in-american-indian-sle-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology